Physician profile

James Patton Webb

General Practice (Dentist) · Gulfport, MS

NPI 1093128894

$2,698.51

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$70.01

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Zimvie INC. $1,689.18 2022
Zimmer Biomet Holdings, INC. $821.92 2019-2022
Dentsply Sirona INC $79.97 2019
Colgate Oral Pharmaceuticals, INC. $28.17 2023-2024
Voco America INC. $23.26 2020-2023 Admira Fusion
Peter Brasseler Holdings, LLC $16.39 2021
Straumann USA LLC $14.68 2024
Biohorizons Implant Systems INC. $13.28 2024 Biohorizons
Philips North America LLC $11.66 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Patton Webb

$2,698.51

in general payments reported 2019-2025

Years
2019-2024
Top company
Zimvie INC.

https://glasscript.com/doctor/564814/james-patton-webb

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.